公开(公告)号：JP2549480B2

公开(公告)日：1996-10-30

申请号：JP32545891

申请日：1991-12-10

Applicant: HOECHST JAPAN

Inventor： MORIOKA HIROKO ,  TAKANO MITSURU

IPC: A61K31/52 ,  A61K31/522 ,  A61P13/02 ,  A61P15/00 ,  C07D473/06

公开(公告)号：JPH08184718A

公开(公告)日：1996-07-16

申请号：JP32872994

申请日：1994-12-28

Applicant: HOECHST JAPAN

Inventor： OKANIWA KO

IPC: C08G73/10 ,  G02B1/04 ,  G02B6/12 ,  G02B6/13

Abstract: PURPOSE: To form the excellent optical waveguide which has a little light loss by using specific polyimide, obtained from tetracarboxylic acid or its derivative and diamine acid, as a constituent element of the optical waveguide. CONSTITUTION: A waveguide layer contains photosensitive fluorine-containing polyimide having >=1 kind of repetitive unit shown by a formula I. In the formula, R is anyone of groups expressed by a formula II, R anyone of groups expressed by a formula III, X anyone of groups expressed by a formula IV, and Rf, R'f, and R''f some of groups expressed by a formula 5. The photosensitive fluorine-containing polyimide having repetitive units shown by the formula I can contain >=2 different kinds of the formulas II and III in R and/or R as the repetitive units.

公开(公告)号：JPH08170002A

公开(公告)日：1996-07-02

申请号：JP25990295

申请日：1995-10-06

Applicant: HOECHST JAPAN

Inventor： HARADA TAKAMASA ,  ITO HARUHIKO ,  UBUKATA MASAMI ,  NOZAWA FUMIE

IPC: C08G77/42 ,  C08L31/02 ,  C08L31/04 ,  C08L33/04 ,  C08L83/04 ,  C08L83/10 ,  C09K19/56 ,  G02F1/1337

Abstract: PURPOSE: To obtain the subject composition comprising the mixture of a polymer containing a siloxane as a constituent with a specific homopolymer, excellent in adhesivity to glass substrates, reduced in the visual dependency of display characteristics, and useful for oriented films, etc. CONSTITUTION: This composition comprises the mixture of (A) a block copolymer containing a siloxane as a constituent and preferably further containing fluorine atoms with (B) a homopolymer or copolymer having repeating units of the formula [X is H, F, CH3 , CF3 , CN, CH2 -CH3 ; Z is single bond, O, (C=O), (C=O)-O, O-(C=O), O-(C=O)-(CH2 )n-(C=O)-O, (n) is 0-20; R is H, an alkyl, an unsaturated aliphatic hydrocarbon, a cycloalkyl, an aryl, an (un)saturated heterogeneous ring, their derivatives] [e.g. polymethyl (meth)acrylate].

公开(公告)号：JPH08143470A

公开(公告)日：1996-06-04

申请号：JP28491094

申请日：1994-11-18

Applicant: HOECHST JAPAN

Inventor： SAITO MASANORI ,  ASAKURA EISAKU ,  MATSUDA TAMOTSU

IPC: A61K9/08 ,  A61K38/55 ,  A61P7/02 ,  C07K14/81 ,  C07K14/815

Abstract: PURPOSE: To obtain an agent for the treatment of diffuse intravascular coagulation syndrome to be used in the form of intravenous drip by using hirudin as an active component. CONSTITUTION: The objective agent contains 0.005-0.038mg/ml (50-380 ATU/ml) of hirudin or a gene-recombinant hirudin derivative expressed by formula as an active component and is formed in the form of intravenous drip to get a daily administration rate of 500-1,000ml. It is especially preferable from the balance of the drug effect and the side effect by administering hirudin or its derivative by intravenous drip at a rate of 0.005mg/kg (50 ATU/kg) to 0.01mg/kg (100 ATU/kg) per hour. The administration rate of the agent in the case of treating diffuse intravascular coagulation syndrome is 1/10 to 1/5 of conventional intravenous drip. It has extremely low bleeding risk and high therapeutic effect. 1 ATU corresponds to the amount of hirudin to inhibit (neutralize) 1 unit (IU) of thrombin.

公开(公告)号：JPH08134453A

公开(公告)日：1996-05-28

申请号：JP27941194

申请日：1994-11-14

Applicant: HOECHST JAPAN

Inventor： NONAKA TOSHIAKI ,  RI KEI ,  YAMAGUCHI HIDEMASA ,  TAKECHI AYAKO

IPC: G02F1/13 ,  C09K19/38 ,  C09K19/40

Abstract: PURPOSE: To provide a stable ferroelectric liq. crystal display element which exhibits a good uniform orientation state, good switching characteristics, and threshold value characteristics not varying even after long storage. CONSTITUTION: A ferroelectric liq. crystal compsn. is provided which contains a polymer having at least one kind of alkylene ether linkage represented by the general formula: -(R1 -O)n - (wherein R1 is 2-5C alkylene; and n is an integer of 4-20).

公开(公告)号：JPH0843651A

公开(公告)日：1996-02-16

申请号：JP18351394

申请日：1994-08-04

Applicant: HOECHST JAPAN

Inventor： OKANIWA KO

IPC: G02B6/122 ,  G02B6/30

Abstract: PURPOSE:To provide an optical waveguide element which exhibits resistance to positional deviation between the light exit faces of an LD or optical fiber and the incident face of a waveguide and enables optical coupling with high efficiency. CONSTITUTION:This optical waveguide element is constituted by further forming the second optical waveguide 3 having a refractive index ncp (ncp>=ng) on the first optical waveguide 2 which is formed on a clad layer 1 having a refractive index nc1 and has a refractive index ng (ng>nc1). The sectional shape of the second optical waveguide 3 has a tapered structure of the film thickness decreasing successively according to parting from the contact surface with the first optical waveguide 2, and further, the taper angle theta of the tapered structure is so set as to satisfy the equations. The equations thetaa={90 deg.-arcsin(neff/ncp)}/2, theta

公开(公告)号：JPH083058A

公开(公告)日：1996-01-09

申请号：JP13527594

申请日：1994-06-17

Applicant: HOECHST JAPAN

Inventor： KATO MASAKAZU ,  KITAMURA KAZUYUKI

IPC: A61K38/00 ,  A61K38/17 ,  A61P19/10 ,  A61P43/00

Abstract: PURPOSE:To obtain a medicine for bone metabolic disease suitable for preventing and treating osteoporosis and hypercalcemia, etc., showing inhibitory action on bone resorption, comprising a mammalian IL-1 receptor as an active ingredient. CONSTITUTION:This medicine for bone metabolic disease comprises a mammalian IL-1 receptor of a soluble fragment such as a human I type IL-1 receptor such as a protein comprising 1st to 312nd amino acids of an amino acid sequence of the formula. A dose of the active ingredient per adult daily is preferably 1-500mug.

公开(公告)号：JPH07309778A

公开(公告)日：1995-11-28

申请号：JP10673894

申请日：1994-05-20

Applicant: HOECHST JAPAN

Inventor： KOYAMA MASAYOSHI ,  TAKAHASHI MIKIKO

IPC: A61K38/46 ,  A61P43/00 ,  C07K14/47

Abstract: PURPOSE:To obtain a new therapeutic agent for wound, containing a ribonuclease such as a ribonuclease BL4, a ribonuclease PL3 or ribonuclease HT-29 as the active component, having a promotion effect on growth of fibroblast and reduced in side effects. CONSTITUTION:The new therapeutic agent for wound having a promotion effect on growth of fibroblast, reduced in side effects and, e.g. capable of being locally applied directly to a diseased part is obtained by using one or more kinds of ribonucleases, e.g. a ribonuclease BL4 such as bovine ribonuclease BL4 having an amino acid sequence containing an amino acid sequence represented by formula I (Xaa is Pyro-Gln or Glu), a ribonuclease PL3 such as swine ribonuclease PL3 having an amino acid sequence containing an amino acid sequence expressed by formula II and ribonuclease HT29 as the active component, mixing a water-soluble base therewith and conducting preparation of the resultant mixture.

公开(公告)号：JPH07289116A

公开(公告)日：1995-11-07

申请号：JP11020294

申请日：1994-04-27

Applicant: HOECHST JAPAN

Inventor： TADA NORIHIRO ,  SATO MASAHIRO ,  KOBAYASHI TAKASHI ,  IKEDA TORU ,  HIROKAWA MASAIKU

IPC: A01K67/027 ,  C07K14/34 ,  C12N5/10 ,  C12N15/09 ,  C12N15/85

Abstract: PURPOSE:To obtain a transgenic animal of metabolic bone disease model whose osteoblast is specifically damaged by introducing a fused recombinant gene having a gene coding for a diphtheria toxin A chain in the downstream of a promoter of osteocalcin gene. CONSTITUTION:A fused recombinant gene having a gene coding for a diphtheria toxin A chain (DT-A chain) in the downstream of a promoter of osteocalcin (OC) gene (e.g. transgene in plasmid pOC/DT-A-1) is introduced into a non-human spinal animal. The transgene is injected into a fertilized egg and introduced by transplantation of oviduct. The obtained transgenic animal is a useful model of bone disease accompanying loss, reduction of osteoblast or the lowering of its function and influence upon remodeling of bone due to the loss of osteoblast and specificality of OC tissue can be elucidated.

公开(公告)号：JPH07285856A

公开(公告)日：1995-10-31

申请号：JP8285294

申请日：1994-04-21

Applicant: HOECHST JAPAN

Inventor： TOBE HIROYASU ,  KITAMURA KAZUYUKI ,  KOMIYAMA YASUSHI

IPC: A61K36/18 ,  A61K31/12 ,  A61P19/10 ,  A61P43/00 ,  C07C49/84

Abstract: PURPOSE:To obtain the subject medicine, containing xanthohumol contained in a hop extract as an active ingredient, having strong inhibiting actions on bone resorption and low toxicity and useful for treating and preventing osteoporosis. CONSTITUTION:This therapeutic agent for osteoporosis contains xanthohumol, expressed by the formula and obtained by the purification thereof from a hop which is a natural raw material or the chemical synthesis as an active ingredient. Furthermore, the daily dose is usually preferably 0.1-2g (about 1.5-30mg/kg) expressed in terms of the xanthohumol for an adult.